Clinical-stage immunotherapy firm Alpine Immune Sciences and biopharmaceutical company AbbVie have signed an option and license agreement potentially worth $805m, for ALPN-101 drug.

ALPN-101, a phase 2-ready dual CD28 / ICOS costimulation antagonist is set to be tested in systemic lupus erythematosus and in other autoimmune diseases.

The drug inhibits the CD28 and ICOS T-cell costimulatory pathways being developed to treat severe inflammatory diseases.

Under the deal, AbbVie is paying Alpine an upfront payment of $60m for rights to ALPN-101. Alpine is eligible to receive a further $805m if the drug meets several milestones.

Alpine Immune will undertake a phase 2 study in systemic lupus erythematosus during the option period. AbbVie, on the other hand, will carry out all future clinical development, manufacturing and commercialisation activities for ALPN-101.

The deal validates Alpine Immune’s Directed Evolution platform that yielded several product candidates, including ALPN-101.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

AbbVie senior vice president and chief scientific officer Tom Hudson said: “AbbVie’s expertise in Immunology has led to remarkable breakthroughs in the treatment of autoimmune diseases.

“ALPN-101’s dual mechanism of action has compelling potential as a next-generation treatment in systemic lupus erythematosus and other autoimmune diseases. We are excited to partner with the team at Alpine on the development of this novel therapeutic.”

In a first-in-human study in adult healthy volunteers, Alpine Immune observed favourable safety and tolerability, pharmacokinetics and pharmacodynamics.

Alpine Immune said by simultaneously blocking two costimulatory pathways, ALPN-101 has the potential to enhance outcomes in patients suffering from severe autoimmune / inflammatory disease.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now